BioPharma Credit PLC
BPCP.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | £56,200 | £45,312 | £79,145 | £57,221 |
| % Growth | 24% | -42.7% | 38.3% | – |
| Cost of Goods Sold | £7,289 | £0 | £0 | £0 |
| Gross Profit | £83,779 | £45,312 | £79,145 | £57,221 |
| % Margin | 149.1% | 100% | 100% | 100% |
| R&D Expenses | £0 | £0 | £0 | £0 |
| G&A Expenses | £11,145 | -£5,249 | £7,218 | £19,693 |
| SG&A Expenses | £11,145 | -£5,069 | £7,218 | £19,693 |
| Sales & Mktg Exp. | £0 | £180 | £0 | £0 |
| Other Operating Expenses | £0 | £130 | £0 | £0 |
| Operating Expenses | £11,145 | -£4,939 | £7,218 | £19,693 |
| Operating Income | £72,634 | £50,251 | £71,927 | £37,528 |
| % Margin | 129.2% | 110.9% | 90.9% | 65.6% |
| Other Income/Exp. Net | £149 | £89 | -£89 | -£5 |
| Pre-Tax Income | £72,783 | £50,340 | £71,838 | £37,523 |
| Tax Expense | £0 | £0 | £0 | -£7 |
| Net Income | £53,018 | £50,340 | £71,838 | £37,523 |
| % Margin | 94.3% | 111.1% | 90.8% | 65.6% |
| EPS | 0.046 | 0.042 | 0.058 | 0.029 |
| % Growth | 9.8% | -27.2% | 100.3% | – |
| EPS Diluted | 0.046 | 0.042 | 0.058 | 0.029 |
| Weighted Avg Shares Out | 1,150,156 | 1,222,360 | 1,246,106 | 1,302,701 |
| Weighted Avg Shares Out Dil | 1,150,151 | 1,222,360 | 1,246,077 | 1,302,669 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £1,490 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | -£72,758 | £71,838 | -£71,838 | -£37,530 |
| EBITDA | £53,000 | £0 | £0 | -£7 |
| % Margin | 94.3% | 0% | 0% | -0% |